Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition: An Update for Clinicians

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Circulation

• Publication date

  2005-04-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.0000160860.36911.BDPMID 15824213
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS)

  2004cited by this paper
• Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib

  2004cited by this paper
• Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

  2004cited by this paper
• Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

  2004cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004cited by this paper
• High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease.

  2004cited by this paper
• Thematic review series: The Pathogenesis of Atherosclerosis Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.R400001-JLR200 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.

  2004cited by this paper
• Endothelial lipase and cholesterol metabolism

  2004cited by this paper
• Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

  2004cited by this paper
• Increasing HDL Cholesterol Levels.

  2004cited by this paper
• Red pepper attenuates cholesteryl ester transfer protein activity and atherosclerosis in cholesterol-fed rabbits.

  2003cited by this paper
• Antiatherothrombotic effects of nicotinic acid.

  2003cited by this paper
• Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals.

  2003cited by this paper
• A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin

  2003cited by this paper
• Unique lipoprotein phenotype and genotype associated with exceptional longevity.

  2003cited by this paper
• Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism

  2003cited by this paper
• Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment

  2003cited by this paper
• Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

  2003cited by this paper
• Cholesteryl ester transfer protein activity and atherogenic parameters in rabbits supplemented with cholesterol and garlic powder.

  2003cited by this paper
• The safety and immunogenicity of a CETP vaccine in healthy adults.

  2003cited by this paper
• Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease.

  2003cited by this paper
• Oral Synthetic Phospholipid (DMPC) Raises High-Density Lipoprotein Cholesterol Levels, Improves High-Density Lipoprotein Function, and Markedly Reduces Atherosclerosis in Apolipoprotein E–Null Mice

  2003cited by this paper
• Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux

  2003cited by this paper
• Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis

  2003cited by this paper
• Regulation of reverse cholesterol transport and clinical implications.

  2003cited by this paper
• Alterations in high‐density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins

  2003cited by this paper
• Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia.

  2002cited by this paper
• Increased serum cholesteryl ester transfer protein in obese children.

  2002cited by this paper
• Recombinant Apolipoprotein A-IMilano Infusion Into Rabbit Carotid Artery Rapidly Removes Lipid From Fatty Streaks

  2002cited by this paper
• Low-density lipoprotein lowering and atherosclerosis progression: does more mean less?

  2002cited by this paper
• Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study

  2002cited by this paper
• Effect of HMG-CoA reductase inhibitor on plasma cholesteryl ester transfer protein activity in primary hypercholesterolemia: comparison among CETP/TaqIB genotype subgroups.

  2002cited by this paper
• Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage.

  2002cited by this paper
• The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis.

  2002cited by this paper
• Relationship Between Cholesteryl Ester Transfer Protein and Atherogenic Lipoprotein Profile in Morbidly Obese Women

  2002cited by this paper
• Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

  2001cited by this paper
• Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II

  2001cited by this paper
• High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice: Potential Implications for Acute Plaque Stabilization

  2001cited by this paper
• A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids.

  2001cited by this paper
• Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I

  2001cited by this paper
• The distribution and production of cholesteryl ester transfer protein in the human aortic wall.

  2001cited by this paper
• Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients.

  2001cited by this paper
• A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

  2000cited by this paper
• Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men

  2000cited by this paper
• Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris.

  2000cited by this paper
• Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody.

  2000cited by this paper
• The aggressive low density lipoprotein lowering controversy.

  2000cited by this paper
• Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene.

  2000cited by this paper
• Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.

  2000cited by this paper
• Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene‐environment interaction

  2000cited by this paper
• Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis

  2000cited by this paper
• Cholesteryl ester transfer protein and atherosclerosis

  2000cited by this paper
• Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression.

  1999cited by this paper
• Cholesteryl Ester Transfer Protein Corrects Dysfunctional High Density Lipoproteins and Reduces Aortic Atherosclerosis in Lecithin Cholesterol Acyltransferase Transgenic Mice*

  1999cited by this paper
• Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.

  1999cited by this paper
• Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits*

  1998cited by this paper
• A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency.

  1998cited by this paper
• Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice.

  1998cited by this paper
• Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia.

  1998cited by this paper
• Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin.

  1998cited by this paper
• Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.

  1997cited by this paper
• Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters.

  1996cited by this paper
• Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis.

  1996cited by this paper
• Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.

  1996cited by this paper
• Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene.

  1995cited by this paper
• Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.

  1995cited by this paper
• Cholesteryl ester transfer protein inhibition in hypercholesterolemic hamsters: Kinetics of apoprotein changes

  1995cited by this paper
• Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits.

  1994cited by this paper
• Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency.

  1993cited by this paper
• Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein

  1993cited by this paper
• Efficacy of lipid profiles in prediction of coronary disease.

  1992cited by this paper
• Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice.

  1991cited by this paper
• Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia.

  1991cited by this paper
• Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.

  1990cited by this paper
• Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.

  1990cited by this paper
• Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism.

  1989cited by this paper
• Cholesteryl-Ester Transfer Activityの欠損を示す家族性高HDL血症の1家系

  1987cited by this paper
• Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia.

  1985cited by this paper
• High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

  1977cited by this paper

• Specific Lipid Abnormalities Are Inherently Associated with Late-Onset Alzheimer's Disease

  2025cites this paper
• Expressing the Human Cholesteryl Ester Transfer Protein Minigene Improves Diet-Induced Fatty Liver and Insulin Resistance in Female Mice

  2022cites this paper
• THE EFFECT OF SEMBUNG LEAF EXTRACT (BLUMEA BALSAMIFERA) ON THE NUMBER AND DIAMETER OF RATS LEYDIG CELLS INDUCED BY HIGH-FAT DIET

  2021cites this paper
• The role of cholesteryl ester transfer protein TaqIB polymorphism in young atherosclerotic heart disease

  2019cites this paper
• Correlation of serum cholestryl ester transfer protein (CETP) level with lipid profile in young myocardial infarction patients

  2019cites this paper
• CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet

  2018cites this paper
• Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing.

  2017cites this paper
• Chemistry and Antidiabetic Effects of Phlogacanthus thyrsiflorus Nees Flowers

  2016cites this paper
• Cholesterol Absorption and Metabolism.

  2016cites this paper
• Implications of reverse cholesterol transport: recent studies.

  2015cites this paper
• Efeito farmacogenético do polimorfismo Ala16Val do gene da MnSOD na resposta de pacientes hipercolesterolêmicos a rosuvastatina

  2015cites this paper
• Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine.

  2015cites this paper
• Haemostatic risk factors in dyslipidemic rabbits: role of 10-dehydrogingerdione as a new hypolipemic agent

  2015cites this paper
• Effect of polycan, a β-glucan originating from Aureobasidium, on a high-fat diet-induced hyperlipemic hamster model

  2015cites this paper
• Non-statin therapies for CKD with dyslipidemia

  2014cites this paper
• Ethylacetate extracts of the muscles of Anguilla japonica suppress glucose levels in db/db mice via activation of AMP-activated protein kinase

  2014cites this paper
• Low molecular weight fucoidan (LMWF) improves ER stress-reduced insulin sensitivity through AMPK activation in L6 myotubes and restores lipid homeostasis in a mouse model of type 2 diabetes

  2013cites this paper
• Glyceollin improves endoplasmic reticulum stress-induced insulin resistance through CaMKK-AMPK pathway in L6 myotubes.

  2013cites this paper
• Low Molecular Weight Fucoidan Improves Endoplasmic Reticulum Stress-Reduced Insulin Sensitivity through AMP-Activated Protein Kinase Activation in L6 Myotubes and Restores Lipid Homeostasis in a Mouse Model of Type 2 Diabetes

  2013cites this paper
• The efficiency of dyslipidemia control in real clinical practice and the possibilities of its correction in patients with coronary heart disease and diabetes mellitus in the long -term use of simvastatin

  2013cites this paper
• Efficacy of Hyeongbangjihwhang-tang on the 5/6 Nephrectomy(NTX) induced Chronic Renal Failure(CRF) Rats

  2013cites this paper
• Low Molecular Weight Fucoidan Improves Endoplasmic Reticulum Stress-Reduced Insulin Sensitivity through AMP-Activated Protein Kinase Activation in L 6 Myotubes and Restores Lipid Homeostasis in a Mouse Model of Type 2 Diabetes s

  2013cites this paper
• DEVELOPING AND OPTIMIZING A VALIDATED RP-HPLC METHOD FOR THE ANALYSIS OF AMLODIPINE AND EZETIMIBE WITH ATORVASTATIN IN PHARMACEUTICAL DOSAGE FORMS APPLYING RESPONSE SURFACE METHODOLOGY

  2012cites this paper
• HDL-C as a new therapeutic target in the treatment of dyslipidemia -

  2012cites this paper
• Investigation of the Association between Metabolic Syndrome and Disease Activity in Rheumatoid Arthritis

  2011cites this paper
• Reverse cholesterol transport is elevated in carboxyl ester lipase‐knockout mice

  2011cites this paper
• Fermented garlic protects diabetic, obese mice when fed a high-fat diet by antioxidant effects.

  2011cites this paper
• A better understanding of recent coronary heart disease mortality trends and determinants

  2011cites this paper
• Ineffective statin monotherapy: alternative therapeutic strategy

  2011cites this paper
• EGYETEMI DOKTORI (Ph.D.) ÉRTEKEZÉS Az atorvastatin kezelés és az uncoupling protein-2 hatása és szerepe a zsíranyagcserében

  2010cites this paper
• Efeito da dieta rica em colesterol e gordura saturada sobre o metabolismo da lipoproteína de alta densidade (HDL) em hamsters

  2010cites this paper
• HDL im Rahmen der Atherogenese und HDL-Steigerung durch CETP-Inhibition

  2010cites this paper
• Coronary Artery Disease? Cholesteryl Ester Transfer Protein Inhibition: The Next Frontier in Combating

  2010cites this paper
• High-density lipoprotein subclasses are a potential intermediary between alcohol intake and reduced risk of cardiovascular disease: The Rancho Bernardo Study

  2010cites this paper
• HDL therapy: two kinds of right?

  2010cites this paper
• Prebeta1-HDL is elevated in the fasting state, but markedly reduced postprandially in poorly controlled type 2 diabetic patients.

  2009cites this paper
• Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs.

  2009cites this paper
• EFEITOS DA Campomanesia xanthocarpa EM PARÂMETROS BIOQUÍMICOS, HEMATOLÓGICOS E DE ESTRESSE OXITATIVO EM PACIENTES HIPERCOLESTEROLÊMICOS

  2009cites this paper
• Relations Between Atherogenic Index of Plasma, Ratio of Small Dense Low Density Lipoprotein/Lecithin Cholesterol Acyl Transferase and Ratio of Small Dense Low Density Lipoprotein/Cholesteryl Ester Transfer Protein of Controlled and Uncontrolled Type 2 DM

  2009cites this paper
• Efeito em hamsters da suplementação dietética com gorduras ricas em ácidos graxos saturados, monoinsaturados ou poliinsaturados sobre a transferência de lípides para a lipoproteína de alta densidade (HDL)

  2009cites this paper
• Therapies to Increase ApoA-I and HDL-Cholesterol Levels

  2008cites this paper
• The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.

  2008cites this paper
• High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease

  2008cites this paper
• The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.

  2008cites this paper
• HDL Metabolism and CETP Inhibition

  2008influential citation
• Hypolipidemic and Hepatoprotecitive Effects of Picrorrhiza Rhizoma in High Fat Diet Supplied Mice. A Pevention Sudy.

  2008cites this paper
• Atheroprotective effects of HDL: beyond reverse cholesterol transport.

  2008cites this paper
• High HDL‐cholesterol in women with rheumatoid arthritis on low‐dose glucocorticoid therapy

  2008cites this paper
• CETP activity variation in mice does not affect two major HDL antiatherogenic properties: macrophage-specific reverse cholesterol transport and LDL antioxidant protection.

  2008influential citation
• HDL-cholesterol modulation and its impact on the management of cardiovascular risk

  2008cites this paper
• Intervening on HDL‐C: Is it possible? Does it work? *

  2007cites this paper
• Raising HDL‐C: back to the future?

  2007cites this paper
• Will torcetrapib be the next big thing in coronary heart disease risk reduction?

  2007cites this paper
• Risk factors for coronary artery disease in patients with elevated high-density lipoprotein cholesterol.

  2007cites this paper
• Atherosclerosis in SR-BI Deficient Mice Cholesteryl Ester Transfer Protein ( CETP ) Expression Protects Against Diet Induced

  2007cites this paper
• Serum High-Density Lipoprotein Cholesterol Levels Epistatic Effect of Cholesteryl Ester Transfer Protein and Hepatic Lipase on

  2007cites this paper
• Effect of Long-term Epoetin Treatment on Serum Levels of High-density Lipoprotein (HDL) and HDL-associated Enzymes in Patients with Chronic Kidney Disease

  2007cites this paper
• Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease

  2007cites this paper
• Cholesteryl Ester Transfer Protein (CETP) Expression Protects Against Diet Induced Atherosclerosis in SR-BI Deficient Mice

  2007cites this paper
• Emerging HDL-based therapies for atherothrombotic vascular disease

  2007cites this paper
• Voodoo medicine — cardiovascular trials jinxed in New Orleans Dr Anthony Wierzbicki discusses highlights of the 56th Annual Scientific Session of American College of Cardiology held at Morial Conventions Centre in New Orleans March 24th—27th, 2007

  2007cites this paper
• Effect of drugs on high-density lipoprotein.

  2007cites this paper
• Cholesteryl ester transfer protein gene haplotypes, plasma high-density lipoprotein levels and the risk of coronary heart disease

  2007cites this paper
• Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels.

  2007cites this paper
• Effect of hypoalbuminemia on the increased serum cholesteryl ester transfer protein concentration in children with idiopathic nephrotic syndrome.

  2007cites this paper
• Controversies in Cardiology 1 Controversies in stable coronary artery disease

  2006cites this paper
• Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study

  2006cites this paper
• Hypolipemic effect of water extracts of Picrorrhiza rhizoma in PX-407 induced hyperlipemic ICR mouse model with hepatoprotective effects: a prevention study.

  2006cites this paper
• High-density lipoproteins: metabolic, clinical, epidemiological and therapeutic intervention aspects. An update for clinicians.

  2006cites this paper
• Detection and Treatment of Vulnerable Plaques and Vulnerable Patients: Novel Approaches to Prevention of Coronary Events

  2006cites this paper
• Cholesteryl ester transfer protein inhibition: the next frontier in combating coronary artery disease?

  2006cites this paper
• Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.

  2006cites this paper
• Apolipoprotein A-I and risk for cardiovascular diseases

  2006cites this paper
• Pathogenesis and treatment of diabetic vascular disease – illustrated by two cases

  2006cites this paper
• Management of dyslipidaemias

  2006cites this paper
• Emerging strategies for increasing high-density lipoprotein.

  2006cites this paper
• Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.

  2006cites this paper
• High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease

  2006cites this paper
• Controversies in stable coronary artery disease.

  2006cites this paper
• Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?

  2006influential citation
• High-Density Lipoproteins: Metabolic, Clinical, Epidemiological and Therapeutic Intervention Aspects. An Update for Clinicians

  2006cites this paper
• HDL/apoA-I infusion for atherosclerosis management: an emerging therapeutic paradigm

  2006cites this paper
• Human monogenic disorders — a source of novel drug targets

  2006cites this paper
• Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease.

  2006cites this paper
• Cholesteryl ester transfer protein inhibitors as potential new therapies for coronary artery disease

  2006cites this paper
• Cholesteryl ester transfer protein inhibitors: new strategies for raising high-density lipoprotein cholesterol

  2006cites this paper
• Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD.

  2006cites this paper
• Current and Future Treatment of Metabolic Syndrome and Type 2 Diabetes in Children and Adolescents

  2005cites this paper
• Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management.

  2005cites this paper
• Cholesteryl Ester Transfer Protein Directly Mediates Selective Uptake of High Density Lipoprotein Cholesteryl Esters by the Liver

  2005cites this paper
• HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study

  2005cites this paper
• Torcetrapib/atorvastatin combination therapy

  2005cites this paper
• Pharmacological basis of different targets for the treatment of atherosclerosis

  2005cites this paper